Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 13, 2015

Primary Completion Date

July 4, 2018

Study Completion Date

July 4, 2018

Conditions
Solid Tumors
Interventions
DRUG

YYB101

"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CellabMED

INDUSTRY